Literature DB >> 10620120

Regulation of HMG-CoA synthase and HMG-CoA reductase by insulin and epidermal growth factor in HaCaT keratinocytes.

I R Harris1, H Höppner, W Siefken, A M Farrell, K P Wittern.   

Abstract

Synthesis of cholesterol, via the isoprenoid/mevalonate pathway, is required for keratinocyte growth and differentiation, and maintenance of the stratum corneum lipid lamellae. 3-hydroxy-3-methylglutaryl coenzyme A synthase catalyzes the first step in isoprenoid/mevalonate synthesis and under some conditions controls the flux into the pathway. We have investigated whether selected growth factors and hormones could increase 3-hydroxy-3-methylglutaryl coenzyme A synthase mRNA in keratinocytes. Northern blotting was used to demonstrate that 10 microg per ml insulin and 0.1 microg per ml epidermal growth factor both increased steady-state levels of 3-hydroxy-3-methylglutaryl coenzyme A synthase mRNA by 2.5 and 6-fold, respectively. Epidermal growth factor and insulin also increased 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme activity. 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter activity in a luciferase reporter construct was increased 2-fold by insulin and 2.9-fold by epidermal growth factor. When a mutation in the sterol regulatory element was introduced into the 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter, activity was not increased by insulin, but was increased by epidermal growth factor. Mutation of an AP-1 site in the 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter did not affect the increase in activity following treatment with insulin or epidermal growth factor. Therefore, 3-hydroxy-3-methylglutaryl coenzyme A synthase expression in keratinocytes is regulated by insulin and epidermal growth factor by different mechanisms. These results suggest a role for hormones and growth factors in the control of epidermal cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620120     DOI: 10.1046/j.1523-1747.2000.00822.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor.

Authors:  Sasa Vukelic; Olivera Stojadinovic; Irena Pastar; Constantinos Vouthounis; Agata Krzyzanowska; Sharmistha Das; Herbert H Samuels; Marjana Tomic-Canic
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

2.  Trans, trans-farnesol as a mevalonate-derived inducer of murine 3T3-F442A pre-adipocyte differentiation.

Authors:  Sheida Torabi; Huanbiao Mo
Journal:  Exp Biol Med (Maywood)       Date:  2015-12-08

3.  Biphasic regulation of HMG-CoA reductase expression and activity during wound healing and its functional role in the control of keratinocyte angiogenic and proliferative responses.

Authors:  Dana Schiefelbein; Itamar Goren; Beate Fisslthaler; Helmut Schmidt; Gerd Geisslinger; Josef Pfeilschifter; Stefan Frank
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

4.  Regulation of protein-coding gene and long noncoding RNA pairs in liver of conventional and germ-free mice following oral PBDE exposure.

Authors:  Cindy Yanfei Li; Julia Yue Cui
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

5.  A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin.

Authors:  Irene Santalices; Carlos Vázquez-Vázquez; Manuel J Santander-Ortega; Victoria Lozano; Francisca Araújo; Bruno Sarmento; Neha Shrestha; Veronique Préat; Miguel Chenlo; Clara V Alvarez; Federico Benetti; Juan Cuñarro; Sulay Tovar; Dolores Torres; María José Alonso
Journal:  Drug Deliv Transl Res       Date:  2021-02-11       Impact factor: 4.617

6.  Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System.

Authors:  Joanne Heade; Fiona McCartney; Miguel Chenlo; Olga Moreno Marro; Maja Severic; Robert Kent; Sinead B Bleiel; Clara V Alvarez; Brendan T Griffin; David J Brayden
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.